Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Cholangiocarcinoma
ADR ID BADD_A00897
ADR Hierarchy
09      Hepatobiliary disorders
09.04      Hepatobiliary neoplasms
09.04.02      Malignant hepatobiliary neoplasms
09.04.02.009      Cholangiocarcinoma
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.07      Hepatobiliary neoplasms malignant and unspecified
16.07.01      Bile duct neoplasms malignant
16.07.01.002      Cholangiocarcinoma
Description A malignant tumor arising from the epithelium of the BILE DUCTS. | A carcinoma that originates in the intrahepatic bile duct epithelium of the intrahepatic biliary tree. Malignant lesions are solid, nodular, and grayish. Most cases are adenocarcinomas. Somatic mutations in BAP1, ARID1A, PBRM1, IDH1, and IDH2 genes have been identified. OMIM: 615619 [MeSH]
MedDRA Code 10008593
MeSH ID D018281; D018285
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Cholangiocarcinoma | Cholangiocarcinoma non-resectable | Cholangiocarcinoma NOS | Cholangiocarcinoma recurrent | Cholangiocarcinoma resectable | Intrahepatic bile duct cancer | Intrahepatic bile duct cancer non-resectable | Intrahepatic bile duct cancer NOS | Intrahepatic bile duct cancer recurrent | Intrahepatic bile duct cancer resectable | Intrahepatic bile duct carcinoma | Intrahepatic bile duct carcinoma non-resectable | Intrahepatic bile duct carcinoma recurrent | Intrahepatic bile duct carcinoma resectable | Malignant neoplasm of intrahepatic bile ducts | Malignant neoplasm of intrahepatic bile ducts non-resectable | Malignant neoplasm of intrahepatic bile ducts recurrent | Malignant neoplasm of intrahepatic bile ducts resectable | Intrahepatic cholangiocarcinoma | Intrahepatic cholangiocarcinoma recurrent | Klatskin tumor | Klatskin tumour | Hilar cholangiocarcinoma | Extrahepatic cholangiocarcinoma | Cholangiocarcinoma metastatic | Cholangiocarcinomas | Cholangiocellular Carcinoma | Carcinoma, Cholangiocellular | Carcinomas, Cholangiocellular | Cholangiocellular Carcinomas | Extrahepatic Cholangiocarcinoma | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinomas, Extrahepatic | Extrahepatic Cholangiocarcinomas | Intrahepatic Cholangiocarcinoma | Cholangiocarcinoma, Intrahepatic | Cholangiocarcinomas, Intrahepatic | Intrahepatic Cholangiocarcinomas
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00100Ambrisentan0.000120%
BADD_D00151Apixaban0.000065%
BADD_D00347Candesartan cilexetil0.002103%
BADD_D00349Capecitabine0.000112%
BADD_D00563Dabigatran0.000245%
BADD_D00589Dasatinib0.000112%
BADD_D00680Dimethyl fumarate0.000400%
BADD_D00701Dofetilide0.000085%
BADD_D00775Enzalutamide0.000501%
BADD_D00858Everolimus0.000229%
BADD_D01023Glimepiride0.000042%
BADD_D01136Imatinib0.000168%
BADD_D01248Lapatinib0.000112%
BADD_D01253Lenalidomide0.000964%
BADD_D01336Macitentan0.000120%
BADD_D01352Maraviroc--
BADD_D01506Muromonab-cd3--
BADD_D01653Paclitaxel0.000560%
BADD_D01831Prednisolone0.000140%
BADD_D01858Propagermanium--
BADD_D01909Ramipril0.000093%
BADD_D01913Ranitidine0.000063%
BADD_D01933Ribavirin0.011868%
BADD_D02029Sitagliptin0.000080%
BADD_D02053Sofosbuvir0.000282%
BADD_D02066Spironolactone0.000037%
BADD_D02106Tadalafil0.000195%
BADD_D02331Valsartan0.000265%
BADD_D02517Enasidenib0.000246%
BADD_D02582Pemigatinib0.000336%
The 1th Page    1    Total 1 Pages